Advertisement

Ads Placeholder
Loading...

ImmuCell Corporation

ICCC•NASDAQ
Healthcare
Biotechnology
$7.73
$0.62(8.72%)
U.S. Market opens in 13h 57m

ImmuCell Corporation (ICCC) Stock Overview

Explore ImmuCell Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap69.9M
P/E Ratio-66.98
EPS (TTM)$-0.12
ROE-0.04%
Fundamental Analysis

AI Price Forecasts

1 Month$6.18
3 Months$6.17
1 Year Target$7.91

ICCC Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of ImmuCell Corporation (ICCC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 73.35, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $7.91.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -66.98 and a market capitalization of 69.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
8.72%
5-Day Change
14.52%
1-Month Change
21.35%
3-Month Change
16.77%
6-Month Change
18.56%
Year-to-Date (YTD) Change
25.69%
1-Year Change
40.55%
3-Year Change
57.43%
5-Year Change
-16.52%
All-Time (Max) Change
-17.59%

Contact Information

https://immucell.com
207 878 2770
56 Evergreen Drive, Portland, ME, 04103

Company Facts

69 Employees
IPO DateMay 5, 1987
CountryUS
Actively Trading

Frequently Asked Questions